Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1239 results about "Amyloid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Amyloids are aggregates of proteins that become folded into a shape that allows many copies of that protein to stick together, forming fibrils. In the human body, amyloids have been linked to the development of various diseases. Pathogenic amyloids form when previously healthy proteins lose their normal physiological functions and form fibrous deposits in plaques around cells which can disrupt the healthy function of tissues and organs.
Therapeutic formulations for the treatment of beta-amyloid related diseases
InactiveUS20050031651A1Impairs daily activityAvoid impairmentPharmaceutical delivery mechanismPharmaceutical active ingredientsCytotoxicityAmyloid
This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.
Owner:BELLUS HEALTH (INT) LTD (CH)
Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase
InactiveUS20050282826A1Elevated β-amyloid levelTreatment, prevention or amelioration of a disease orBiocideNervous disorderGreek letter betaMedicine
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.
Owner:WYETH
Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
InactiveUS20050282825A1Elevated β-amyloid levelTreatment, prevention or amelioration of a disease orBiocideNervous disorderGreek letter betaMedicine
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.
Owner:WYETH LLC
Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase
![Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase](https://images-eureka.patsnap.com/patent_img/9b458263-f0d6-4bd1-8869-72f2e272686a/US20070072925A1-20070329-C00001.png "Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase")
![Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase](https://images-eureka.patsnap.com/patent_img/9b458263-f0d6-4bd1-8869-72f2e272686a/US20070072925A1-20070329-C00002.png "Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase")
![Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase](https://images-eureka.patsnap.com/patent_img/9b458263-f0d6-4bd1-8869-72f2e272686a/US20070072925A1-20070329-C00003.png "Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase")
Owner:WYETH LLC
Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
Owner:WYETH LLC
Non-invasive magnetic or electrical nerve stimulation to treat or prevent dementia
ActiveUS20130066392A1Inhibition of excitementAvoid stimulationElectroencephalographyElectrotherapyAdrenergicMedicine
Devices, systems and methods are disclosed for treating or preventing dementia, such as Alzheimer's disease. The methods comprise transmitting impulses of energy non-invasively to selected nerve fibers, particularly those in a vagus nerve, that modulate the activity of a patient's locus ceruleus. The transmitted energy impulses, comprising magnetic and / or electrical energy, stimulate the selected nerve fibers to cause the locus ceruleus to release norepinephrine into regions of the brain that contain beta-amyloids. The norepinephrine counteracts neuroinflammation that would damage neurons in those regions and the locus ceruleus, thereby arresting or slowing the progression of the disease in the patient.
Owner:ELECTROCORE
Novel method for down-regulation of amyloid
A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and / or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.
Owner:H LUNDBECK AS
Humanized Abeta antibodies for use in improving cognition
InactiveUS20060198851A1Increase awarenessReduce the burden onNervous disorderImmunoglobulins against animals/humansDiseaseAntiendomysial antibodies
The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase
![Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase](https://images-eureka.patsnap.com/patent_img/ff3938b9-266f-464f-a99f-be2342573144/US20070203116A1-20070830-C00001.png "Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase")
![Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase](https://images-eureka.patsnap.com/patent_img/ff3938b9-266f-464f-a99f-be2342573144/US20070203116A1-20070830-C00002.png "Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase")
![Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase](https://images-eureka.patsnap.com/patent_img/ff3938b9-266f-464f-a99f-be2342573144/US20070203116A1-20070830-C00003.png "Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase")
Owner:WYETH
Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.
Owner:TEL AVIV UNIV FUTURE TECH DEVMENT
Abeta antibodies for use in improving cognition
InactiveUS20060257396A1Prevents glycosylationRapidly improving cognitionNervous disorderImmunoglobulins against animals/humansAmyloidHumanized antibody
The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.
Owner:TEL AVIV UNIV FUTURE TECH DEVMENT
Use of antibody
InactiveUS20070031416A1Nervous disorderImmunoglobulins against animals/humansMonoclonal antibodyAmyloid
The present invention intended to provide an agent for preventing / treating Alzheimer's disease. More specifically, the present invention provides an agent for preventing / treating Alzheimer's disease, etc., which comprises a monoclonal antibody specifically reacting with a partial peptide at the C-terminal region of a β-amyloid or its derivatives.
Owner:TAKEDA PHARMA CO LTD
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
InactiveUS20080014194A1Improves motor characteristicInhibit deteriorationNervous disorderImmunoglobulins against animals/humansTherapeutic treatmentAmyloid
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
InactiveUS7122374B1Many symptomReduce riskAnimal cellsImmunoglobulins against animals/humansSide effectAmyloid beta
AβN3pE-42 is a β amyloid protein that accumulates specifically as a major constituent of senile plaque in the brains of both sporadic and familial Alzheimer's disease patients. The invention provides antibodies that specifically recognize AβN3pE-42 and can be expected to have a strong β amyloid-removing action. Particularly, humanized antibodies against AβN3pE-42 are useful to treat human neurodegenerative diseases. Further, since AβN3pE-42 is localized in the brain, the antibodies of the invention can avoid side effects such as kidney disorders caused by the formation of antigen-antibody complex in the blood. An agent for gene therapy using a vector in which a cDNA encoding a protein comprises the antigen-binding region of the antibody can be an efficient therapeutic drug for removing β amyloid from the brain.
Owner:SAIDO TAKAOMI +1
Imaging agents for detecting neurological disorders
ActiveUS20100239496A1Isotope introduction to heterocyclic compoundsNervous disorderImaging agentMethod of images
Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and / or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.
Owner:ELI LILLY & CO
Humanized Anti-Amyloid Antibody
Compositions for treating neurodegenerative or amyloidgenic disorders such as Alzheimer's disease (AD) are provided. More particularly, humanized anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
Owner:AMGEN INC
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
InactiveUS20120323214A1Reduce and preventAvoid destructionNervous disorderHead electrodesApoptosisExcitotoxicity
This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.
Owner:WEDGE THERAPEUTICS
Anti-amyloid antibodies and uses thereof
Compositions for treating neurodegenerative or amyloidogenic disorders such as Alzheimer's disease (AD) are provided. More particularly, anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
Owner:AMGEN INC
Anti-amyloid antibodies, compositions, methods and uses
The present invention relates to at least one novel anti-amyloid antibody, including isolated nucleic acids that encode at least one anti-amyloid antibody, amyloid, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Owner:CENTOCOR +1
Filamentous bacteriophage displaying a beta-amyloid epitope
A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g. Alzheimer's disease) which rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g. Alzheimer's disease) which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.
Owner:RAMOT AT TEL AVIV UNIV LTD
Methods of preventing, treating and diagnosing disorders of protein aggregation
Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.
Owner:MCLAURIN JOANNE
Benzothiepin derivatives, process for the preparation of the same and uses thereof
InactiveUS6355672B1Potent osteogenesis promoting effectLow toxicityBiocideOrganic chemistryDiseaseHydrogen atom
The invention provides compounds of the formula:wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or salts thereof, which are useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect.The present invention relates to an amine compound having an excellent effect of inhibiting production and / or secretion of amyloid-b protein, a production and use thereof. Especially, it is effective for preventing and / or treating, for example, neurodegenerative diseases, amyloid angiopathy, neurological disorders caused by cerebrovascular disorders, and so forth.
Owner:TAKEDA PHARMA CO LTD
Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives
InactiveUS20020022621A1Alter one or more clinical indicia of disease activityBiocidePeptide/protein ingredientsAmyloidDisease cause
There is provided a series of arylacetamidoalanyl derivatives of benzodiazepinones of Formula I wherein R1 through R7 and n are defined herein, which are inhibitors of beta-amyloid peptide (beta-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extract cellular deposition of amyloid.
Owner:BRISTOL MYERS SQUIBB CO
Antibodies specific for toxic amyloid beta protein oligomers
InactiveUS20050124016A1Animal cellsImmunoglobulins against animals/humansOligomerMonoclonal antibody
The present invention provides compositions and methods for diagnosing Alzheimer's disease (AD). In particular, the present invention provides monoclonal antibodies that specifically bind to soluble, non-fibrillar oligomeric amyloid β protein assemblies proteolytically derived from the transmembrane amyloid precursor protein (APP) while not reacting with fibrillar amyloid β protein assemblies, monoclonal antibodies that specifically bind to fibrillar amyloid β protein assemblies that do not react with soluble, non-fibrillar oligomeric amyloid β protein assemblies, and methods of use of these compositions in the diagnosis of Alzheimer's disease, as well as methods to monitor treatment and / or disease progression of AD in patients.
Owner:NORTHWESTERN UNIV +1
Cyclic amine bace-1 inhibitors having a benzamide substituent
ActiveUS20050119227A1Inhibition formationBiocideNervous disorderHMG-CoA reductaseNeuro-degenerative disease
Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein [0001]R1 is [0002]R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
Owner:PHARMACOPEIA DRUG DISCOVERY +1
Use of anti-amyloid agents for treating and typing pathogen infections
Owner:RAMOT AT TEL AVIV UNIV LTD
Monoclonal Antibodies That Target Pathological Assemblies Of Amyloid B (Abeta)
ActiveUS20070218499A1Nervous disorderImmunoglobulins against animals/humansOligomerMonoclonal antibody
Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.
Owner:NORTHWESTERN UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com